216 related articles for article (PubMed ID: 33208551)
1. A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells.
Matus EI; Sparkes A; Gariépy J
JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33208551
[TBL] [Abstract][Full Text] [Related]
2. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
Li Q; Yu B; Grover AC; Zeng X; Chang AE
J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
[TBL] [Abstract][Full Text] [Related]
4. Transient stimulation expands superior antitumor T cells for adoptive therapy.
Kagoya Y; Nakatsugawa M; Ochi T; Cen Y; Guo T; Anczurowski M; Saso K; Butler MO; Hirano N
JCI Insight; 2017 Jan; 2(2):e89580. PubMed ID: 28138559
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
6. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
7. T cell stimulation and expansion by SunTag-based clustering of anti-CD3/CD28 scFv.
Zhong K; Liu Z; Li H; Zhao S; Wang Y; Guo W; Zheng X; Yang H; Guo G; Zhou L; Xu J; Tong A
Aging (Albany NY); 2020 Jun; 12(11):11061-11070. PubMed ID: 32526703
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells ex vivo.
Gong W; Ji M; Cao Z; Wang L; Qian Y; Hu M; Qian L; Pan X
Cell Mol Immunol; 2008 Feb; 5(1):47-53. PubMed ID: 18318994
[TBL] [Abstract][Full Text] [Related]
9. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies.
Kalamasz D; Long SA; Taniguchi R; Buckner JH; Berenson RJ; Bonyhadi M
J Immunother; 2004; 27(5):405-18. PubMed ID: 15314550
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28-Stimulated T Cell IFN-γ and TNF-α Production.
Calianese D; Kreiss T; Kasikara C; Davra V; Lahey KC; Gadiyar V; Geng K; Singh S; Honnen W; Jaijyan DK; Reichman C; Siekierka J; Gennaro ML; Kotenko SV; Ucker DS; Brekken RA; Pinter A; Birge RB; Choudhary A
J Immunol; 2021 Jul; 207(2):436-448. PubMed ID: 34215655
[TBL] [Abstract][Full Text] [Related]
11. Soluble and Immobilized Anti-CD3/28 Distinctively Expand and Differentiate Primary Human T Cells: An Implication for Adoptive T Cell Therapy.
Soltantoye T; Akbari B; Mirzaei HR; Hadjati J
Iran J Allergy Asthma Immunol; 2022 Dec; 21(6):630-637. PubMed ID: 36640054
[TBL] [Abstract][Full Text] [Related]
12. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
[TBL] [Abstract][Full Text] [Related]
13. Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
Hombach A; Tillmann T; Jensen M; Heuser C; Sircar R; Diehl V; Kruis W; Pohl C
J Immunother; 1997 Sep; 20(5):325-33. PubMed ID: 9336739
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody.
Makrigiannis AP; Musgrave BL; Hoskin DW
J Leukoc Biol; 1999 Nov; 66(5):792-802. PubMed ID: 10577511
[TBL] [Abstract][Full Text] [Related]
15. A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors.
Yang S; Dudley ME; Rosenberg SA; Morgan RA
J Immunother; 2010; 33(6):648-58. PubMed ID: 20551831
[TBL] [Abstract][Full Text] [Related]
16. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
17. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies.
Bohlen H; Hopff T; Manzke O; Engert A; Kube D; Wickramanayake PD; Diehl V; Tesch H
Blood; 1993 Sep; 82(6):1803-12. PubMed ID: 7691238
[TBL] [Abstract][Full Text] [Related]
18. A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.
Alvarez-Fernández C; Escribà-Garcia L; Vidal S; Sierra J; Briones J
J Transl Med; 2016 Jul; 14(1):214. PubMed ID: 27435312
[TBL] [Abstract][Full Text] [Related]
19. IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.
Santegoets SJ; Turksma AW; Suhoski MM; Stam AG; Albelda SM; Hooijberg E; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; Powell DJ; June CH; de Gruijl TD
J Transl Med; 2013 Feb; 11():37. PubMed ID: 23402380
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.
Davis CC; Marti LC; Sempowski GD; Jeyaraj DA; Szabolcs P
Cancer Res; 2010 Jul; 70(13):5249-58. PubMed ID: 20530666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
